ZYMERGEN INC (ZY)

US98985X1000 - Common Stock

2.43  +0.04 (+1.67%)

Fundamental Rating

2

Overall ZY gets a fundamental rating of 2 out of 10. We evaluated ZY against 84 industry peers in the Chemicals industry. ZY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ZY is valued expensive and it does not seem to be growing.



0

1. Profitability

1.1 Basic Checks

In the past year ZY has reported negative net income.
ZY had a negative operating cash flow in the past year.

1.2 Ratios

Industry RankSector Rank
ROA -77.49%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -1836.72%
PM (TTM) -2508.94%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

5

2. Health

2.1 Basic Checks

ZY does not have a ROIC to compare to the WACC, probably because it is not profitable.
ZY has more shares outstanding than it did 1 year ago.
The debt/assets ratio for ZY has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -4.65, we must say that ZY is in the distress zone and has some risk of bankruptcy.
ZY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.65
ROIC/WACCN/A
WACC12.14%

2.3 Liquidity

ZY has a Current Ratio of 4.59. This indicates that ZY is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 4.47 indicates that ZY has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 4.59
Quick Ratio 4.47

3

3. Growth

3.1 Past

ZY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 53.02%, which is quite impressive.
The Revenue for ZY has decreased by -22.23% in the past year. This is quite bad
EPS 1Y (TTM)53.02%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q13.08%
Revenue 1Y (TTM)-22.23%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q-55.01%

3.2 Future

The Earnings Per Share is expected to grow by 9.49% on average over the next years. This is quite good.
ZY is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 36.42% yearly.
EPS Next Y33.88%
EPS Next 2Y20.08%
EPS Next 3Y20.85%
EPS Next 5Y9.49%
Revenue Next Year-21.93%
Revenue Next 2Y16.02%
Revenue Next 3Y24.75%
Revenue Next 5Y36.42%

3.3 Evolution

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZY. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -0.16

4.3 Compensation for Growth

A more expensive valuation may be justified as ZY's earnings are expected to grow with 20.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.08%
EPS Next 3Y20.85%

0

5. Dividend

5.1 Amount

No dividends for ZY!.
Industry RankSector Rank
Dividend Yield N/A

ZYMERGEN INC

NASDAQ:ZY (10/18/2022, 7:22:57 PM)

2.43

+0.04 (+1.67%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap253.58M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -77.49%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM -1836.72%
PM (TTM) -2508.94%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 4.59
Quick Ratio 4.47
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)53.02%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y33.88%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-22.23%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y